Ex Vivo Pharmacokinetic/Pharmacodynamic Integration Model of Cefquinome Against Escherichia coli in Foals

文献类型： 外文期刊

第一作者： Gao, Tiantian

作者： Gao, Tiantian;Qiu, Di;Li, Yanan;Qiu, Zongsheng;Qi, Jingjing;Li, Shuxin;Guo, Xiaoyan;Gao, Xiang;Ma, Tianwen;Liu, Xuesong;Zhang, Yan;Wang, Ziqi;Ma, Yuhui;Ma, Tianwen

作者机构：

关键词： cefquinome; Escherichia coli; PK/PD model; dose regimen

期刊名称：VETERINARY SCIENCES （ 影响因子：2.3； 五年影响因子：2.4 ）

ISSN：

年卷期： 2025 年 12 卷 4 期

页码：

收录情况： SCI

摘要： Cefquinome is used to treat septicemia caused by Escherichia coli (E. coli) and respiratory infections caused by Streptococcus equi subsp. zooepidemicus in foals. However, studies reporting the use of cefquinome to target E. coli as pathogens of sepsis are lacking. Therefore, this study aimed to determine the optimal dosage regimen for cefquinome against E. coli using a PK/PD model. After the administration of 1 mg/kg cefquinome (intramuscularly or intravenously), blood samples were collected at different time points to determine the serum concentration of cefquinome via HPLC. The pharmacokinetic parameters were evaluated via NCA (WinNonlin 5.2.1 software). The main pharmacokinetic parameters of cefquinome in foals were as follows: after intravenous administration, the elimination half-life (T1/2 beta) was 2.35 h, the area under the curve (AUC0-last) was 12.33 mu gh/mL, the mean residence time (MRT0-last) was 2.67 h, and the clearance rate (CL) was 0.09 L/h/kg. After intramuscular administration, the peak concentration (Cmax) was 0.89 mu g/mL, the time to reach the maximum serum concentration (Tmax) was 2.16 h, T1/2 beta was 4.16 h, AUC0-last was 5.41 mu gh/mL, MRT0-last was 4.92 h, CL was 0.15 L/h/kg, and the absolute bioavailability (F) was 43.86%. An inhibitory sigmoid Emax model was used to integrate the PK/PD indices with ex vivo antimicrobial effects to identify pharmacodynamic targets (PDTs). According to the dose calculation formula, the doses of intramuscularly administered cefquinome required to achieve bacteriostatic effects, bactericidal effects, and bactericidal elimination were 1.10, 1.66, and 2.28 mg/kg, respectively. However, further studies are warranted to verify the therapeutic efficacy of cefquinome in clinical settings.

分类号：

  • 相关文献
作者其他论文 更多>>

微信小程序